Blood samples collected at trial sites in different countries need to be handled and analyzed consistently so that differences in the results reflect the underlying biology rather than avoidable variations in sample management or testing. Getting there depends on more than good science — it depends on how the sample was handled, shipped, and processed between collection and analysis. This is the operational problem central lab services are built to address.

Why Sample Handling Introduces Variability

In a multi-site trial, samples typically pass through several hands: a site coordinator collects them, a courier transports them, and a laboratory processes and analyzes them. Each of these steps can introduce variability if it is not standardized across sites. A site using its own local laboratory, for instance, may apply a different reference range or assay method than a site in another country, even when testing for the same biomarker.

This is the core rationale for routing samples through a coordinated lab network rather than a patchwork of local labs: It can reduce variability by applying standardized sample-handling and testing procedures across study sites, while using reference ranges appropriate to the applicable testing method and study requirements.

Cold Chain Logistics Across Borders

Many biological samples are temperature-sensitive, and their stability can degrade quickly outside a specific range. Cold chain logistics — the combination of validated packaging, temperature monitoring, and controlled transit conditions — is intended to keep a sample within its required temperature band from the moment it is collected to the moment it reaches the lab, even when that journey crosses international borders and customs checkpoints.

Failures in this chain are not always obvious after the fact; a sample that has drifted outside its stability range does not necessarily look different, but the result it produces may no longer be reliable. This is part of why temperature monitoring devices are typically shipped alongside samples rather than relying solely on packaging specifications, giving both the courier and the receiving lab a documented record of the conditions the sample actually experienced.

Where an Integrated Central Lab Service Fits

Sponsors running trials that span multiple countries generally look for a provider whose central lab services function is backed by an established international footprint rather than a series of locally contracted labs assembled study by study. Tigermed lists Central Laboratories among its integrated capabilities, alongside its broader network of more than 180 offices and locations across Asia Pacific, Europe, North America, Latin America, and Africa — a footprint relevant to a sponsor moving samples across several of those same regions within a single trial.

This kind of central lab offering typically sits alongside a company’s quality assurance function rather than operating independently of it. Tigermed’s QA team, which the company describes as operating independently from its clinical operations groups, reports more than 40 in-house auditors and supports GCP, GLP, and GMP audit services — the same audit disciplines relevant to confirming that a central lab’s sample handling and testing processes are functioning as documented over time.

Sample Stability Validation

Before a lab can rely on a given sample-handling protocol, that protocol generally needs to be validated against real stability data — evidence showing how long a specific sample type remains stable under specific storage and transport conditions before analyte degradation affects the result. Without appropriate stability data, a lab may lack sufficient evidence to demonstrate that the sample remains suitable for the intended analysis after two days under the specified transport conditions.

Stability validation work typically has to be repeated or reconfirmed when a study introduces a new sample matrix, a new analyte, or a new shipping route with different transit times, since stability data generated under one set of conditions does not automatically apply to a different one. Sponsors are generally advised to ask a prospective lab partner for validation data specific to the sample types and routes their trial will actually use.

Chain of Custody Documentation

Chain-of-custody documentation provides a traceable record of a sample’s collection, transfers, receipt, processing, and storage, with relevant dates, times, identifiers, and responsible personnel recorded according to the study’s procedures. Each sample is typically assigned a unique identifier at the point of collection, which is then used to track it through shipment, receipt, processing, and storage, usually within a Laboratory Information Management System (LIMS) that records who performed each action and when.

This documentation matters for more than administrative tidiness. If a data query arises during monitoring or a regulatory review, an incomplete chain of custody record can make it difficult to establish whether a sample’s result reflects the true biological value or a handling issue introduced somewhere along the way.

Centralized Processing and Between-Lab Variability

The common thread across cold chain management, stability validation, and chain of custody documentation is that each becomes more consistent when a trial routes its samples through one coordinated central lab process rather than a collection of independently operating local labs. A centralized approach can standardize collection materials, validated shipping conditions, and testing methods across study sites, reducing variability that might otherwise arise from differences between local laboratories.

For sponsors evaluating central clinical laboratories as part of a multi-region trial design, the relevant questions generally include how consistently a provider’s kit production, shipping validation, and chain-of-custody documentation are applied across the specific countries the trial will run in — since a central lab model only reduces variability to the extent its standardized processes are actually followed uniformly across every site.

Companies such as Tigermed, which report both a multi-region office network and an independently structured quality assurance and audit function, illustrate one way these elements are organized under a single provider. As with any lab services decision, sponsors are advised to confirm current validation and accreditation status specific to their trial’s sample types before finalizing a selection.